Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Maintains Buy on Biogen, Lowers Price Target to $442

UBS analyst Colin Bristow maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $475 to $442.

byvishwanath@benzinga.com

September 16, 2021

1 minute read

UBS analyst Colin Bristow maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $475 to $442.

Analyst Ratings

The Latest Analyst Ratings for Pebblebrook Hotel

By Benzinga Insights

Today, 3:39 AM

Over the past 3 months, 5 analysts have published their opinion on Pebblebrook Hotel (NYSE:PEB) stock. These analysts…

PEB

Ducommun Acquires Magnetic Seal For Undisclosed Sum

By Akanksha Bakshi

Today, 3:39 AM

Ducommun Inc (NYSE: DCO) has completed the acquisition of Rhode Island-based Magnetic Seal Corporation (MagSeal). Deal terms were not disclosed.

DCO

News

IHS Markit’s OPIS Expands Daily Compliance Carbon Pricing Services

By Akanksha

Today, 3:39 AM

IHS Markit Ltd (NYSE:INFO) company OPIS (Oil Price Information Service) launched an expansion to its daily compliance carbon pricing services. The OPIS Carbon…

INFO

Barclays Maintains Equal-Weight on American Intl Gr, Raises Price Target to $59

By Benzinga Newsdesk

Today, 3:39 AM

Barclays analyst Tracy Benguigui maintains American Intl Gr (NYSE:AIG) with a Equal-Weight and raises the price target from $53 to $59.

AIG

UBS Maintains Buy on Biogen, Lowers Price Target to $442

Related Posts

The Latest Analyst Ratings for Pebblebrook Hotel

Ducommun Acquires Magnetic Seal For Undisclosed Sum

IHS Markit’s OPIS Expands Daily Compliance Carbon Pricing Services

Barclays Maintains Equal-Weight on American Intl Gr, Raises Price Target to $59